Clinical Trial Update: GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating GL701 (Prestara) in women with systemic lupus erythematosus who are receiving glucocorticoids has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Prestara (GL701)

Snippet

Sponsor: Genelabs Technologies | Conditions: Systemic Lupus Erythematosus | Phase 3 | Status: COMPLETED